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Abstract  
Neurotoxicity is a common side effect of chemotherapy treatment, with unclear 
molecular mechanisms. Clinical studies suggest that the most frequent neurotoxic 
adverse events affect memory and learning, attention, concentration, processing 
speeds and executive function. Emerging preclinical research points toward direct 
cellular toxicity and induction of neuroinflammation as key drivers of neurotoxicity 50 
and subsequent cognitive impairment. Emerging data now show detectable levels of 
some chemotherapeutic agents within the CNS, indicating potential disruption of 
blood brain barrier integrity or transport mechanisms. Blood brain barrier disruption is 
a key aspect of many neurocognitive disorders, particularly those characterised by a 
proinflammatory state. Importantly, many proinflammatory mediators able to 
modulate the blood brain barrier are generated by tissues and organs that are targets 
for chemotherapy-associated toxicities. This review therefore aims to explore the 
hypothesis that peripherally-derived inflammatory cytokines disrupt blood brain 
barrier permeability, thereby increasing direct access of chemotherapeutic agents into 





Neurotoxicity and its associated cognitive manifestations are poorly characterised, dose-
limiting side effects of chemotherapy treatment 1. Clinically, the impact of chemotherapy on 
cognition has been most extensively studied in breast cancer patients 2-4, however it is 
becoming increasingly recognised that cognitive symptoms affect a large portion of patients 
with varying malignancies and treatments 5-8. Despite its prevalence, cognitive dysfunction, 
often referred to as chemobrain, remains an under-reported and ill-defined complication of 
anti-cancer treatment. Cognitive symptoms are vast, but are most commonly reported to affect 70 
memory and learning, attention, concentration, processing speeds and executive function 2, 4, 9, 
10. Importantly, unlike many acute chemotherapy-related toxicities, cognitive dysfunction 
presents both acutely and chronically, compromising quality of life for patients unable to 
return to prior levels of social and academic interaction 11.  
Given its frequency, and its acute and chronic impact, the importance of better understanding 
chemotherapy-induced neurotoxicity has become a priority with an obvious goal of 
developing effective interventions. Like the overwhelming majority of regimen related 
toxicities, changes in neurological function occur in a subset of cancer patients and curiously 
these changes may or may not be associated with structural and functional alterations in the 
brain 12. Compounding our ability to attribute cognitive changes directly to treatment has been 80 
the finding that impairment has been reported among cancer patients who are treatment naïve 
13.  
As yet, the molecular mechanism(s) involved in chemotherapy-induced neurotoxicity have 
not been clearly defined, however there is strong evidence implicating direct cytotoxicity and 
associated inflammatory mechanisms. Currently, the bulk of studies assessing the latter focus 
on neuroinflammatory pathways, however, it is important to consider the impact of cytokines 
derived from the tumor, as well as those elicited by the effect of chemotherapy on normal or 
tumour tissue. Most likely, direct cytotoxicity and neuroinflammation occur in concert with 
cytokine-mediated disruption of the blood brain barrier (BBB) serving to enhance drug 
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penetration to augment local levels and result in amplification of cognitive symptoms.    90 
The finding of detectable levels of systemically administered chemotherapeutic agents within 
the central nervous system (CNS) 14 supports this presumption and implies a level of BBB 
permeability that has not been previously appreciated.  Increased levels of BBB permeability 
suggest that some chemotherapeutic agents are capable of disrupting its integrity, either 
directly or indirectly. Convincing evidence also exists linking BBB dysfunction with a 
proinflammatory state, with BBB dysfunction reported in patients with chronic inflammatory 
diseases as well as being a consequence of many forms of regimen-related peripheral 
toxicities. Among these, chemotherapy-induced mucosal injury, especially of the 
gastrointestinal tract, provides a compelling example of how focal chemotherapy-induced 
tissue damage can serve as a conduit for central neurotoxicity. Of interest, chemotherapy-100 
induced gut toxicity (CIGT) has recently been shown to increase central markers of pain and 
neuroinflammation highlighting the ability of peripherally-derived inflammation to 
profoundly affect CNS function.  
2.0 Structural and neuroimaging studies that define the scope of chemotherapy-
associated changes in the brain 
The neural basis for neurological deficiencies in cancer patients has been investigated with 
both structural and functional neuroimaging. Voxel-based morphometry (VBM) and 
diffusion-tensor imaging (DTI) are structural imaging techniques able to detect changes in 
both white and gray matter , whilst, functional magnetic resonance imaging (fMRI) and 
positron emission tomography (PET) studies enable assessment of functional deficiencies 110 
when structural changes are not evident. While these technologies have not been applied 
broadly, limited data suggest that chemotherapy is consistently associated with, changes in 
white matter (WM) structures. WM hyperintensities and hippocampal lesions have been 
identified using basic neuroimaging techniques in breast cancer patients treated with various 
chemotherapy regimens 17-19.  
T1-VBM studies, an automated and quantitative method of neuroimaging which theoretically 
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provides an unbiased, comprehensive, and highly reliable assessment sensitive to local 
changes 20, 21 have demonstrated diffuse cortical and subcortical WM and bilateral neocortical 
gray matter (GM) volume reductions or deficiencies in the superior frontal gyrus, 
parahippocampal gyrus, cingulate gyrus and the precuneus gyrus 22-24. Based on the spectrum 120 
of neurocognitive symptoms seen in cancer patients and the well documented function of the 
hippocampus, a growing body of research now shows impaired neurogenesis and 
hippocampal function likely contribute to neurotoxicity 25, 26. In support of this, hippocampal 
alterations have been identified in response to a spectrum of chemotherapeutic agents 5, 26-28 in 
a number of patient cohorts.    
Structural changes, indicative of direct neurotoxicity, are often seen in conjunction with 
neurocognitive functional deficiencies detected through DTI and digital symbol testing 
(DST); a measure of processing speed. Although studies are limited in size and number, 
results have indicated associations between the integrity of the corpus collosum and 
processing speeds of patients receiving adjuvant chemotherapy for breast cancer 29. Further 130 
associations have been identified between processing speeds and frontal WM integrity 30. The 
largest study to investigate this association was conducted by Deprez and colleagues (2012) in 
premenopausal women with breast cancer. Patients receiving adjuvant chemotherapy 
exhibited worsening attention, psychomotor speed, verbal learning and memory, as well as 
decreased microstructural integrity in widespread regions of the corona radiata and the corpus 
collosum, compared to matched controls, reinforcing that WM changes may be the source of 
cognitive deficits seen in chemotherapy-treated patients 31.  
Results of neuroimaging studies have been informative relative to describing observed 
structural and functional deficiency relationships associated with cancer- and chemotherapy-
associated cognitive dysfunction. However, they are unable to mechanistically define the 140 
pathogenesis of chemotherapy-associated neurological toxicities. And at this early stage, their 
interpretation is limited by heterogeneity in experimental methodology, and confounded by 
neurological comorbidities commonly seen in cancer patients such as depression and anxiety, 
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which can produce similar structural manifestations 1. Furthermore, the inclusion of 
predominantly elderly patients, a lack pretreatment baseline controls and presence of 
structural deficits in treatment-naïve patients clouds the ability to make definitive conclusions 
regarding the mechanisms of chemotherapy-induced neurotoxcity.   
3.0 Blood brain barrier dysfunction: an accelerant for neurotoxicity?  
The presence of chemotherapeutic agents in the CNS after systemic administration indicates 
their ability to cross the BBB, either physiologically or pathologically 32. Early research has 150 
demonstrated detectable levels of intravenously administered cisplatin, bis-
chloroethylnitrosourea (BCNU) and paclitaxel in the brains of rodents using PET 32, 33. This 
phenomenon has also been seen in higher order primates, with detectable levels of 5-
fluorouracil in the cerebrospinal fluid after intravenous administration 14. Although 
therapeutic drug levels effective for CNS malignancies were not seen, drug concentrations 
were sufficient to induce apoptosis and neuronal damage associated with neurological 
dysfunction 34. In addition to these findings, it is well established that a number of 
proinflammatory cytokines have detrimental effects on tight junctions and thus the integrity 
of the BBB. This is critically important when considering BBB breakdown in cancer patients, 
as there are a number of sources of proinflammatory cytokines, derived from the tumour and 160 
the effects of chemotherapy on normal tissue.  
3.3.1 Mediators of inflammation disrupt blood brain barrier integrity 
The BBB (Figure 1) is highly plastic and can undergo significant modification in response to 
a raft of physiological and pathologies cues. Subsequently, impairment of the BBB has been 
implicated in a number of CNS pathologies, particularly those characterised by a 
proinflammatory state 35 36. For example, traumatic brain injury (TBI) is often accompanied 
by a large inflammatory response resulting in grossly abnormal BBB permeability, the influx 
of inflammatory cells and subsequent oedema 37, 38. A similar mechanism is now also 
hypothesised to play a role in the pathogenesis of stroke in which a weakening of the BBB, 
associated with a transient breakdown of tight junction proteins, is thought to contribute to the 170 
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haemorrhagic transformation manifested by a heightened inflammatory state and worsened 
prognosis 39.  
In light of these clinical associations between inflammation and BBB breakdown, there is 
now a wealth of in vitro and in vivo data demonstrating the ability of proinflammatory 
cytokines to disrupt the BBB (Table 1). From these observations, it is clear that some 
cytokines exclusively affect paracellular barriers (e.g. IL-1β), through breakdown and 
translocation of tight junction proteins, whilst others target transcellular processes mediated 
by caveolae (e.g. TNF). A number of vasogenic agents (histamine, substance P) and 
proteases associated with inflammation, have also been identified to promote BBB 
remodeling. Of interest is the impact of matrix metalloproteinases (MMP) on tight junction 180 
integrity (Table 1) given the high levels of circulating MMPs observed after chemotherapy 40. 
It is well documented that increased MMP activity correlates with elevated permeability of 
both endothelial and epithelial barriers (Table 1), strongly implying MMP-mediated tight 
junction disruption 41-44. Particularly robust evidence supports a role for MMP-mediated tight 
junction disruption in the BBB as endothelial cells, astrocytes and pericytes are all potent 
sources of these signaling proteins 41. Brain-derived microvascular endothelial cells (BMECs) 
exposed to oxidative stress expressed significantly elevated MMP-9 activity paralleled by 
downregulation and redistribution of occludin 45. Numerous preclinical studies also support a 
role for MMP-mediated tight junction disruption 42, 43, 46. For example, MMP-2/-9 levels have 
been shown to be significantly elevated following cerebral ischemia leading to tight junction 190 
protein degradation, increased BBB permeability and oedema 42, 47. Furthermore, inhibition of 
MMP-2/-9 has been shown to reduce vascular permeability and attenuate tight junction 
disruption 42. This is further supported by evidence showing that MMP-9 knockout mice have 
greater ZO-1 expression coupled with decreased BBB permeability and reduced oedema 
following stroke 48. The impact of MMPs on caveolae-mediated transcytosis is now also being 
recognised for its potential role in CNS pathologies characterised by BBB disruption (Table 
1).      
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4.0 Chemotherapy-induced cytokine production, blood brain barrier dysfunction and 
clinical implications for patients   
Virtually every biological substance known to have the capacity to alter the integrity of the 200 
BBB has been shown to be generated by tissues and organs that are targets for chemotherapy-
associated toxicities. Among these, chemotherapy-induced mucosal injury, especially of the 
gastrointestinal tract provides a compelling example of how focally-induced chemotherapy 
tissue damage can serve as a conduit for central neurotoxicity. While suggested by Seigers et 
al., (2011) 49, the potential impact peripheral inflammatory mediators as a driver of central 
toxicity has hardly been explored.   
4.1 Chemotherapy-induced gut toxicity: a potential facilitator of CNS pathology   
We have previously highlighted strong epidemiological data linking the development of 
neurotoxicity and gut toxicity following chemotherapy, and suggest that these off targets 
toxicities may in fact have common molecular roots 50, 51. The development of CIGT is a 210 
dynamic process, characterised by overlapping and simultaneous biological events. Logan et 
al. (2008) demonstrated that the administration of irinotecan, 5-fluoruoracil and methotrexate 
induced significant elevations in TNF, IL-1 and IL-6 in tumour-bearing rats. Importantly, 
these proinflammatory cytokines not only damage surrounding tissue through pro-apoptotic 
signals (e.g. caspases 3 activation), but they are also highly efficient activators of NFB thus 
amplifying the mucotoxic cascade. Furthermore, TNF and IL-1 induce MMP-1, MMP-2 
and MMP-3 activation, which is thought to contribute to development of gut toxicity through 
inflammatory pathways, altered extracellular matrix composition, adhesion molecules and 
tight junction disruption. Toll like receptor (TLR)4-dependent mechanisms have also been 
linked to the development of gut toxicity, with increases in its expression seen following 220 
chemotherapy 52 as well as improvements in symptomatic parameters seen following genetic 
manipulation of its downstream signaling molecules (e.g. MyD88, MD-2) 53 54. This aspect of 
CIGT has significant implications for BBB maintenance, as it is becoming increasingly clear 
that TLR4-dependent signaling pathways are critical for tight junction integrity 55.  
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TLR4-mediated barrier modulation has been shown in both endothelial and epithelial models. 
For example, Gao et al., (2015) recently showed that traumatic brain injury was not only 
associated with traditional proinflammatory markers, but also elevated TLR4 signalling and 
uncontrolled BBB transit. Importantly, administration of a vascular endothelial growth 
inhibitor (VEGI) up-regulated the tight junction proteins (claudin-5, ZO-1, occludin) and 
attenuated TLR4 activation, NF-κB signaling and the production of proinflammatory 230 
cytokines, as well as improving markers of brain injury. Alcohol-induced steatohepatitis is 
also well documented to present with acute intestinal barrier disruption, resulting from 
impaired tight junction protein expression 56. In this study, administration of a TLR4 
monoclonal antibody attenuated both functional and molecular markers of barrier function, 
emphasising the importance of TLR4-mediated tight junction disruption in an inflammatory 
setting.  
TLR4-dependent tight junction disruption has also been shown to occur in response to 
irinotecan treatment in a TLR4 knockout (-/-) mouse model of gut toxicity {Wardill, 2016 
#566}. Following irinotecan, increased permeability of both the intestinal barrier and BBB 
were detected, both seen at 24 h post-treatment. Although TLR4 knockout animals only 240 
showed improvements in intestinal barrier disruption, this study is the first to demonstrate 
central neurotoxic changes in a model of chemotherapy-induced gut toxicity and reinforces 
the bidirectional communication that exists between the gastrointestinal system and CNS. It is 
likely this communication that underpins the prevalent comorbidities affecting these organ 
systems.  
4.2 Intestinal inflammation drives CNS changes   
A number of intestinal pathologies are associated with an increased risk of behavioural 
comorbidities as indicated by increased rates of depression, mood disorders and cognitive 
dysfunction in patients with inflammatory bowel disease (IBD) 57. For example, elevated 
circulating proinflammatory cytokines, increased in intestinal permeability and the number of 250 
circulating monocytes are commonly reported in acute phases of trinitrobenzene sulfonic acid 
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(TNBS)-induced colitis in mice. 58. Importantly, these are accompanied by localised breaches 
in the BBB 59 leading to increased neuroinflammation 60, 61 and associated cognitive 
disturbance. These findings are consistent with those of Zonis et al., (2015) who, using a 
different murine IBD model (dextran sodium sulfate), found increased microglial and 
astrocytic reactivity in the hippocampus of treated mice.62. These results also compliment data 
indicating altered neuronal function and increased anxiety-like behaviour in models of 
parasitic gut inflammation 63, 64.  Other reports support the concept that patients with chronic 
inflammatory states initiated by autoimmune diseases, cancer or infections are at higher risk 
for central neurological pathology and that there is a high likelihood that such changes are 260 
mediated by proinflammatory cytokines directly impacting the brain 65.  
5.0 Neuroinflammation and cognitive dysfunction   
Increased systemic proinflammatory cytokine production has been previously suggested as a 
candidate mechanism for cognitive dysfunction in cancer patients 28. It is therefore possible 
that proinflammatory cytokines may be involved in several aspects of neurotoxicity by; (1) 
increasing BBB transit, and (2) permitting neuroinflammation and associated tissue 
manifestations.  
Substantial data, from a spectrum of clinical settings, highlight links between peripheral 
inflammation and cognitive symptoms. For example, peripheral activation of the immune 
system by a subseptic dose of lipopolysaccharide (LPS) has been shown to increase cytokine 270 
expression within the brain 67-69 at levels associated with learning and memory disruption in 
both models of disease and health 70-72.  In healthy volunteers, LPS lead to increased levels of 
IL-1, TNFα and IL-6 resulting in impaired working memory and cognitive dysfunction 73. 
Similarly, increased peripheral inflammation has also been associated with gradual cognitive 
decline and the development of dementia in the elderly population 74.  
Interestingly, the use of IFNα and IL-2 (proinflammatory cytokines) as anti-cancer agents is 
highly linked to the development of depression and other cognitive impairments 75, 76, 
however, there is only limited clinical data from cancer patients in which correlations 
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between circulating cytokines and cognitive function have been evaluated. Meyers et al., 
(2009) reported an association between elevated levels of circulating IL-6 and worsened 280 
executive function in patients with acute myeloid leukemia 77. In addition, elevated IL-6 and 
TNFα seen in chemotherapy-treated breast cancer survivors correlated with persistent 
hippocampal structural changes and reduced verbal memory performance 78, 79 well beyond 
the period during which patients received drug infusions.   
When looking at other CNS pathologies characterised by neuroinflammation and cognitive 
impairment, Alzheimer’s disease (AD) provides additional insight. Patients with AD often 
have elevated levels of TNFα in the cerebrospinal fluid and parenchyma 80, as well as 
expressing TNFα-related polymorphisms 81. The pathological level of cytokines resulting in 
this chronic inflammatory state mimics that noted in cancer patients and perpetuates neuronal 
loss and cognitive decline 82. Importantly, treatment with anti-TNFα agents in patients with 290 
AD has been shown to favorably impact the development of cognitive dysfunction 83, 84. Of 
particular importance to our proposed hypothesis is that AD is often accompanied by 
increased BBB transit 85, leading to heightened inflammatory influx and worsened clinical 
outcomes.  
5.1 Tumour-dependent cytokine production  
Further confounding our understanding of how peripheral inflammation, BBB disruption and 
neuroinflammation contribute to cognitive dysfunction is the fact that results from clinical 
studies are neither uniform nor concrete. Cognitive dysfunction has been reported in patients 
with breast cancer or colorectal cancer after diagnosis, but before the administration of any 
anti-cancer treatment 87. Similarly, in a recent study comparing patients with localised 300 
colorectal cancer (n=289) who received or did not receive chemotherapy, patients with 
metastatic or recurrent colorectal cancer (CRC) (n=73) and healthy controls, Vardy et al., 
(2015) reported significant differences in cognitive dysfunction prior to, and following, 
treatment between patients with CRC and healthy controls 13.  Surprisingly, there was no 
difference in the degree of cognitive dysfunction between patients who received 
 13 
chemotherapy and those who did not. In addition, the extent of disease (local vs. metastatic) 
did not effect neurological function clouding understanding of tumour-driven effects on 
cognition. While levels of proinflammatory cytokine levels were elevated in the CRC cohorts 
vs. controls, there was no statistically significant relationship between them and cognitive 
dysfunction. Patel et al’s study of 174 newly diagnosed patients with breast cancer also 310 
reported baseline levels of cognitive dysfunction and elevations in proinflammatory cytokine 
levels (TNF) 87.  However, elevations in TNF were no higher in cancer patients compared to a 
non-cancer, demographically similar control group.  
The findings of these, and similar studies, demonstrate the complexities of both the clinical 
and biological elements associated with cancer treatment-related cognitive dysfunction. First, 
the intrinsic and extrinsic biological activities associated with tumours have likely been 
underestimated. Tumours may actively produce inflammatory mediators as a consequence of 
local oxidative stress or stimulate inflammation in response to their presence 88. These 
findings might account for baseline cognitive dysfunction. Nonetheless, the lack of significant 
differences in cytokine levels between recently diagnosed cancer patients and non-cancer 320 
controls clouds definitive conclusions.  
6.0 The significance of symptom chronicity       
Despite patient and study heterogeneity and methodological limitations, neurotoxicity is 
defined by the chronicity of symptoms which often persist long after treatment cessation 31. It 
has been reported that patients treated with high dose chemotherapy and those that receive 
autologous haemopoietic stem cell transplantation have significant impairments in cognitive 
function up to 1 year after cessation of their treatment 89. The longevity of cognitive 
symptoms has also been assessed in survivors of childhood acute lymphoblastic leukaemia 6-
18 years after remission 90. Deficits in figural memory as well as reduced hippocampal 
volume were also noted. Similarly, in breast cancer patients, chemotherapy treatment resulted 330 
in reduced gray matter volume in the right parahippocampal gyrus compared to untreated 
cancer patients, which correlated with reduced memory performance at 1 but not 3 years post-
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treatment 23. These studies are somewhat complimented by two prospective studies that show 
hippocampal volume reductions at 1 month following chemotherapy treatment, which was 
lost at further time points (1 year) 91.  More persistent changes were observed in a recent 
investigation of 19 breast cancer patients 92, who showed right hippocampal gray matter 
volume reductions at both 1 month and 1 year after treatment completion. 
Although variations exist in the time-course of these symptoms, chronicity is almost always 
reported and is a defining characteristic of neurotoxicity. Given the relatively short half-life of 
many chemotherapeutic agents, the chronicity of symptoms is biologically significant, and 340 
suggests that the impact of direct cytotoxicity would presumably be minimal; with chronic, 
reactive inflammatory processes, a more likely candidate. However, it is important to consider 
that neurotoxicity is unlikely to be attributable to a single mechanism, rather, various 
mechanisms may converge additively or synergistically to result in the heterogeneous 
symptoms seen in patients (Figure 2). This is well described by Dietrich et al., (2015) who 
highlights key mechanistic drivers such as oxidative stress, direct cellular toxicity and 
inflammation that contribute to altered cellular kinetics in the hippocampus as well as 
neurovascular/BBB disruption 5. If a prolonged period of inflammation is present, either 
systemically or centrally, altered BBB transit could parallel the chronic, long-term changes in 
seen in patients and may provide a better biological understanding.  350 
7.0 Conclusion  
Regimen-related toxicities are poorly characterised and often have significant effects on 
patient quality of life. We have previously highlighted the importance of symptom clusters, 
emphasising the possibility of common underlying mechanisms, which could perhaps be 
simultaneously targeted 93. Cognitive impairment is particularly devastating to patients, and 
currently has no universally accepted mechanism. This review has proposed that, contrary to 
traditional beliefs, chemotherapeutic agents can in fact gain access to the CNS. Importantly, 
we suggest that this is likely due to upregulated and uncontrolled BBB transit. The BBB, like 
many interfaces within the body, is subject to intense modification highlighting the plasticity 
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of tight junctions and transcytotic mediators. Based on symptom clustering and potential 360 
linkages between the gut and CNS, we suggest that peripherally-derived inflammatory 
mediators are responsible for inducing BBB dysfunction, thus permitting central 
neurotoxicity. Importantly, neurotoxic changes may occur through the direct actions of the 
chemotherapeutic drug itself, or present as the behavioural manifestation of 
neuroinflammation. BBB disruption may therefore be the missing link in our understanding of 
how gut/CNS communication is involved in the development of two critically important 
regimen-related toxicities. Furthermore, it presents as an exciting opportunity to target 
peripheral inflammation and achieve wider reaching clinical outcomes.   
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10.0 Figure legends  
Figure 1 Blood brain barrier transport mechanisms. Cerebral endothelial cells of the 
blood brain barrier (Panel A) have specialised circumferential tight junctions and 
intracellular caveolae, which regulate blood brain barrier transit (Panel B). Tight 
junctions are highly plastic, multi-protein structures traversing the intercellular 
junction (Panel C). Each tight junction comprises the cytoplasmic protein family 
zonular occludens (-1, -.2, -3) and the transmembraneous protein families claudin, 690 
JAMs and occludin. Caveolae, comprised of Cav-1, Cav-2 and Cav-3, control 
transcellular permeability within the blood brain barrier (Panel D).   
Figure 2 Schematic highlighting multifactorial pathobiology of cognitive 
dysfunction. Many cognitive disorders are characterised by blood brain barrier 
disruption and neuroinflammation. The impact of peripheral inflammation on central 
neurovascular integrity and the subsequent development of neuroinflammation is now 
considered a key driver in many neurological disease characterised by systemic 
inflammation. Blood brain barrier disruption may therefore compliment what is 
currently understood about neurotoxicity, by enhancing exposure of the CNS to 
chemotherapeutic agents (direct neurotoxicity) and permitting neuroinflammation 700 
(indirect).      
 
